Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1374 | Pituitary Clinical | ICEECE2012

Circulating total and high molecular weight adiponectin levels are lower in adult GH deficient subjects

Caputo M. , Prodam F. , Garbaccio V. , Sama M. , Zavattaro M. , Pagano L. , Marzullo P. , Aimaretti G.

Introduction: Regulation of adiponectin in GH deficiency (GHD), which presents visceral obesity, is still a matter of debate. No studies have evaluated circulating adiponectin isoforms in adult GHD subjects. Aim of this study was to evaluate total adiponectin (TA) and its isoforms (high molecular weight: HMW, medium molecular weight: MMW, low molecular weight: LMW) in hypopituitary adult subjects with and without GHD, in relation to weight, IGF1 and GH levels.<p class="abs...

ea0022p421 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Thyroid Incidentaloma identified by 18F-Fluorodeoxyglucose Positron Emission Tomography with CT (FDG-PET/CT): clinical relevance

Pagano Loredana , Sama MariaTeresa , Rudoni Marco , Belcastro Sara , Busti Arianna , Caputo Marina , Inglese Eugenio , Aimaretti Gianluca

Thyroid incidentalomas was defined as newly identified thyroid lesions encountered during imaging study for non-thyroid diseases. In the last years, the use of FDG-PET/CT for staging of metastatic diseases was increased. The aim of this retrospective study was to evaluate the FDG-PET/CT uptake, to identify a SUVmax cut off predictive of malignancy and to determine the FDG-PET/CT prognostic role in patients with thyroid incidentalomas. 42 patients (ptx) with incidental thyroid ...

ea0016p287 | Endocrine tumours | ECE2008

The role of 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG/PET-CT) in the follow-up of differentiated thyroid cancer (DTC)

Pagano Loredana , Klain Michele , Pulcrano Melania , Ippolito Serena , Lombardi Gaetano , Salvatore Marco , Biondi Bernadette

Aim: To address the role of FDG/PET-CT in the follow-up of DTC.Methods: About 110 consecutive patients (86 female, 24 male, mean age 45±13 years), with DTC were selected between 1999 and 2006. All patients underwent total thyroidectomy, radioiodine ablation and had undetectable serum thyroglobulin (Tg) during L-T4 suppressive therapy and negative serum TgAb. The follow-up included a yearly clinical examination with n...

ea0011p330 | Diabetes, metabolism and cardiovascular | ECE2006

How does glucose insulin potassium improve haemodynamic performance? Evidence for beta-adrenoreceptor and sarcoplasmic reticulum calcium ATPase up-regulation

Ranasinghe AM , Quinn DW , McCabe CJ , Pagano D , Franklyn JA , Bonser RS

Objectives: Glucose insulin potassium (GIK) improves haemodynamic performance following coronary artery bypass graft surgery (CABG). We postulated that this might be secondary to beta-1 adrenergic receptor (ADRB1) up-regulation and changes in myocyte calcium handling.Methods: We performed a randomised double-blind placebo-controlled trial on patients undergoing first time elective/urgent on-pump CABG (LREC approval obtained). A cohort of 48 patients rand...

ea0009p31 | Diabetes and metabolism | BES2005

Elevated endotoxin levels as a mediator of consistent chronic sub-clinical inflammation in CABG patients

Baker A , Silva N , Ranasinghe A , Pagano D , Bonser R , Kumar S , McTernan P

Chronic sub-clinical inflammation is associated with increased risk of type 2 diabetes and cardiovascular disease. Patients undergoing CABG are at high risk of further cardiovascular events and also demonstrate sub-clinical inflammation. We therefore investigated alterations in the relative balance between pro-inflammatory agents, such as hsCRP versus changes in anti-inflammatory factors (adiponectin) and as such the potential molecular pathways mediating these changes. The ai...

ea0081p474 | Thyroid | ECE2022

Potential risk factors for post-treatment recurrence in patients with intermediate-risk differentiated thyroid carcinoma

Rossi Mattia , Mele Chiara , Rossetto Giaccherino Ruth , Brero Denise , Marsan Giulia , Aimaretti Gianluca , Ghigo Ezio , Pagano Loredana

Introduction: The recurrence rate of intermediate-risk differentiated thyroid carcinoma (DTC) ranges between 5% and 20% and the therapeutic strategy requires further evaluations.Aim: We therefore investigated the potential risk factors for post-treatment recurrence of intermediate-risk DTC at 1 and 3 years from diagnosis.Methods: This retrospective observational study included 121 patients who underwent thyroidectomy for intermedia...

ea0037ep1071 | Thyroid (non-cancer) | ECE2015

Could thyroid replacement therapy not be enough to reduce oxidative stress in hypothyroid patients with Down' syndrome? A cohort study

Villani Emanuele Rocco , Onder Graziano , Carfi Angelo , Pagano Francesco , Raimondo Sebastiano , Di Segni Chantal , Silvestrini Andrea , Meucci Elisabetta , Mancini Antonio

Hypothyroidism and autoimmune thyroiditis are common in patients with DownÂ’ syndrome (DS), leading to common prescription of thyroid replacement therapy. On the other hand, thyroid function is involved in oxidative stress (OS) mechanisms. DS is a well-known high OS condition because several genes involved in OS mechanisms map on chromosome 21 and coenzyme Q10, lipophilic antioxidant, could be more correlated with hypothyroidism than TSH in DS people. To investigate relati...

ea0032p467 | Diabetes | ECE2013

Efficacy and safety of 1 year treatment with Liraglutide in subjects with type 2 diabetes

Prodam Flavia , Zavattaro Marco , Ponziani Chantal , Pagano Loredana , Caputo Marina , Allochis Gabriele , Teresa Sama Maria , Busti Arianna , Aimaretti Gianluca

Introduction: Liraglutide, a GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the efficacy and safety of liraglutide in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). All patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatment, or patients intole...

ea0032p473 | Diabetes | ECE2013

Cardiovascular effects of treatment with Liraglutide in a population with type 2 diabetes

Zavattaro Marco , Prodam Flavia , Grazia Mauri Maria , Pagano Loredana , Caputo Marina , Belcastro Sara , Allochis Gabriele , Aimaretti Gianluca

Introduction: Liraglutide, a human GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the effects of liraglutide on cardiovascular risk factors in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). Patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatmen...

ea0011oc59 | ThyroidOC57 British Thyroid Association Award | ECE2006

Tri-iodothyronine improves haemodynamic performance and is associated with improved myocardial protection post on-pump coronary artery bypass grafting

Ranasinghe AM , Quinn DW , Graham TR , Keogh BE , Mascaro CJ , Rooney SJ , Wilson IC , Pagano D , Franklyn JA , Bonser RS

Objectives: Tri-iodothyronine (T3) can improve cardiovascular performance following cardiac surgery. Its effects on myocardial protection are unknown.Methods: We performed two consecutive randomised double-blind placebo-controlled trials (identical management protocols) on patients undergoing first time isolated elective or urgent on-pump coronary artery bypass graft surgery (CABG). Between January 2000 and September 2004, 440 patients were re...